28 февраля 2017, 17:31

Америка сегодня. ВВП, деловая активность и доверие потребителей.

В данных за четвертый квартал 2016 ВВП прогнозируется аналитиками на уровне 2.1%:

В индексе деловой активности после разочаровывающих данных снова ожидается всплеск к значению 54, которое находится на максимальных отметках за последние пару лет:

Индекс доверия потребителей продолжает устанавливать новые рекорды и этот месяц по прогнозам тоже не станет исключением и покажет отметку 112.1:

Все новости:

Америка сегодня. ВВП, деловая активность и доверие потребителей.

Данные: DTC News, Briefing, Interactive, Economics, Public Sources

американский рынок аналитика NYSE NASDAQ AMEX day trading daytrader DayTraderClub OTCBB проп-трейдинг проп-компании проп TOS TWS акции

Daytrader

Польша

397

5 263

с 25 ноября 2011

86 Комментариев

Daytrader

28 февраля 2017, 17:47

	On The Wires XOMA Corporation (XOMA) announced today that Jim Neal, Chief Executive Officer, will present the company's new strategic initiatives and value drivers at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 11:20 a.m. ET. TeleTech Holdings (TTEC) received a General Services Administration Information Technology (IT) Schedule 70 Contract award in the final quarter of the government's fiscal year 2016. The company's customer experience solutions, offered through TeleTech Technology, are now available to federal, state, and local government buyers through GSA IT Schedule Contract Number GS-35F-151GA. Tonix Pharmaceuticals Holding Corp. (TNXP) announced that it will present at the Cowen and Company 37th Annual Health Care Conference being held March 6-8, 2017 in Boston. Seth Lederman, M.D., president and chief executive officer of Tonix, will provide a corporate update and an overview of the Tonix posttraumatic stress disorder (PTSD) clinical program. TNX-102 SL was recently granted Breakthrough Therapy designation by the U.S. Food and Drug Administration for the treatment of PTSD. Tonix will commence in this quarter a 12-week Phase 3 clinical study, the «HONOR» study, evaluating TNX-102 SL, 5.6 mg, in military-related PTSD. The interim analysis of the HONOR study is expected in the first half of 2018 and topline results are expected in the second half of 2018. The European Commission has approved under the EU Merger Regulation the acquisition of joint control over GfK SE («GfK») of Germany by KKR & Co. (KKR) and GfK-Nürnberg Gesellschaft für Konsum-, Markt- und Absatzforschung e.V of Germany. The Commission concluded that the proposed transaction would raise no competition concerns because the companies are not active on the same or on related markets. The European Commission has approved under the EU Merger Regulation the proposed acquisition of the insurance businesses of American International Group (AIG) in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovakia by Fairfax Financial Holdings (FRFHF). The Commission concluded that the proposed acquisition would raise no competition concerns because the overlaps between the companies' activities are limited. On February 27, 2017 Visteon Corporation (VC) entered into a Master Confirmation and a Supplemental Confirmation with UBS AG, London Branch to purchase shares of its common stock for an initial payment of $125 million. The ASB Agreement was entered into as part of the Company's previously announced share repurchase authorization.

On The Wires

XOMA Corporation (XOMA) announced today that Jim Neal, Chief Executive Officer, will present the company's new strategic initiatives and value drivers at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 11:20 a.m. ET.
TeleTech Holdings (TTEC) received a General Services Administration Information Technology (IT) Schedule 70 Contract award in the final quarter of the government's fiscal year 2016. The company's customer experience solutions, offered through TeleTech Technology, are now available to federal, state, and local government buyers through GSA IT Schedule Contract Number GS-35F-151GA.
Tonix Pharmaceuticals Holding Corp. (TNXP) announced that it will present at the Cowen and Company 37th Annual Health Care Conference being held March 6-8, 2017 in Boston. Seth Lederman, M.D., president and chief executive officer of Tonix, will provide a corporate update and an overview of the Tonix posttraumatic stress disorder (PTSD) clinical program. TNX-102 SL was recently granted Breakthrough Therapy designation by the U.S. Food and Drug Administration for the treatment of PTSD. Tonix will commence in this quarter a 12-week Phase 3 clinical study, the «HONOR» study, evaluating TNX-102 SL, 5.6 mg, in military-related PTSD. The interim analysis of the HONOR study is expected in the first half of 2018 and topline results are expected in the second half of 2018.
The European Commission has approved under the EU Merger Regulation the acquisition of joint control over GfK SE («GfK») of Germany by KKR & Co. (KKR) and GfK-Nürnberg Gesellschaft für Konsum-, Markt- und Absatzforschung e.V of Germany. The Commission concluded that the proposed transaction would raise no competition concerns because the companies are not active on the same or on related markets.
The European Commission has approved under the EU Merger Regulation the proposed acquisition of the insurance businesses of American International Group (AIG) in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovakia by Fairfax Financial Holdings (FRFHF). The Commission concluded that the proposed acquisition would raise no competition concerns because the overlaps between the companies' activities are limited.
On February 27, 2017 Visteon Corporation (VC) entered into a Master Confirmation and a Supplemental Confirmation with UBS AG, London Branch to purchase shares of its common stock for an initial payment of $125 million. The ASB Agreement was entered into as part of the Company's previously announced share repurchase authorization.

Daytrader
28 февраля 2017, 17:47
Durect resumed with a Buy at H.C. Wainwright; tgt $3 (1.02)H.C. Wainwright resumes coverage of DRRX with a Buy and sets target price at $3. Firm's analysis suggests that the Street is barely accruing sufficient value for the Phase 3 Posimir program, while essentially ignoring the novel epigenetic program, thereby creating a free call option for this highly-differentiated proprietary discovery platform. They employ a rNPV valuation model to estimate the intrinsic value of DRRX shares, and arrive at their $3 PT, based on: 1) $1.71 per share, driven by U.S. sales of DUR-928 for AKI (2021 launch; 25% probability of success (POS), $1.1B peak sales); 2) $0.70 per share, driven by royalties on U.S. sales of Posimir (assumes future partner; 75% POS, $500M peak sales; ~22% peak royalties); and 3) $0.52 representing essentially the annuity value of marketed legacy products.
0

Daytrader

28 февраля 2017, 17:48

	Insulet target raised to $50 at Wedbush; Solid quarter, healthy outlook (46.17)Wedbush raises their PODD tgt to $50 from $48 after co posted robust 4Q16 results and issued healthy 2017 guidance, signaling confidence in the overall growth of its diabetes and drug delivery franchises despite a more competitive diabetes landscape. PODD's relatively new mgmt continues to fire on all cylinders with better-than-expected revs across all three of its business segments and solid gross margin expansion. The main takeaways from the quarter were continued strength within co's diabetes franchises (US and OUS), the success of its drug delivery segment, and the confidence that momentum should continue in 2017; Outperform.

Insulet target raised to $50 at Wedbush; Solid quarter, healthy outlook (46.17)Wedbush raises their PODD tgt to $50 from $48 after co posted robust 4Q16 results and issued healthy 2017 guidance, signaling confidence in the overall growth of its diabetes and drug delivery franchises despite a more competitive diabetes landscape. PODD's relatively new mgmt continues to fire on all cylinders with better-than-expected revs across all three of its business segments and solid gross margin expansion. The main takeaways from the quarter were continued strength within co's diabetes franchises (US and OUS), the success of its drug delivery segment, and the confidence that momentum should continue in 2017; Outperform.

Daytrader

28 февраля 2017, 17:48

	Early premarket gappersGapping up: NTRI +20.4%, SBY +16.7%, NSPR +15.4%, INUV +13.5%, DRYS +11.2%, AMRN +7%, FRO +5.2%, KND +5.1%, BWXT +5%, TCMD +4.3%, GOGL +4.3%, NRG +4.2%, PCLN +3.8%, ENDP +3.8%, ICD +3.7%, ESV +2.8%, HTZ +2.7%, HTZ +2.7%, X +2.6%, WUBA +2.5%, SBGL +2.4%, EOG +2.4%, IONS +2.3%, GOLD +2.1%, AMD +2%, LXU +1.8%, GFI +1.7%, HMY +1.6%, ALB +1.5%, PAH +1.5%, RRC +1.4%, AU +1.3%, DB +1.2%, GAIA +1.2%, AKS +1.1%, GDX +1.1%, NEM +1%, SGMO +1% Gapping down: FRGI -15.8%, ESND -14.4%, THC -12.3%, TGT -11.9%, PRGO -11.7%, KONA -9.9%, FTR -9.1%, CEMP -8.3%, NVAX -8%, TTNP -7.9%, HTGM -7.2%, OPHT -7.2%, AAC -6.5%, EXEL -5.6%, WDAY -5.1%, KRA -5%, KTOS -4.9%, ZTO -4.3%, ORA -4.2%, IPWR -4.2%, CPE -4.2%, TCAP -3.8%, VRX -3.1%, PULM -2.8%, FSLR -2.6%, O -2.5%, TRIP -2.3%, GPL -2.1%, STM -2%, SQ -1.8%, BHP -1.8%, ASML -1.8%, TZOO -1.6%, ING -1.5%, KR -1.5%, I -1.4%, APLE -1.2%, WMT -1.1%, JPM -1.1%, HPP -1%, RDS.A -1%, C -0.9%, RIO -0.9%

Early premarket gappersGapping up: NTRI +20.4%, SBY +16.7%, NSPR +15.4%, INUV +13.5%, DRYS +11.2%, AMRN +7%, FRO +5.2%, KND +5.1%, BWXT +5%, TCMD +4.3%, GOGL +4.3%, NRG +4.2%, PCLN +3.8%, ENDP +3.8%, ICD +3.7%, ESV +2.8%, HTZ +2.7%, HTZ +2.7%, X +2.6%, WUBA +2.5%, SBGL +2.4%, EOG +2.4%, IONS +2.3%, GOLD +2.1%, AMD +2%, LXU +1.8%, GFI +1.7%, HMY +1.6%, ALB +1.5%, PAH +1.5%, RRC +1.4%, AU +1.3%, DB +1.2%, GAIA +1.2%, AKS +1.1%, GDX +1.1%, NEM +1%, SGMO +1%

Gapping down: FRGI -15.8%, ESND -14.4%, THC -12.3%, TGT -11.9%, PRGO -11.7%, KONA -9.9%, FTR -9.1%, CEMP -8.3%, NVAX -8%, TTNP -7.9%, HTGM -7.2%, OPHT -7.2%, AAC -6.5%, EXEL -5.6%, WDAY -5.1%, KRA -5%, KTOS -4.9%, ZTO -4.3%, ORA -4.2%, IPWR -4.2%, CPE -4.2%, TCAP -3.8%, VRX -3.1%, PULM -2.8%, FSLR -2.6%, O -2.5%, TRIP -2.3%, GPL -2.1%, STM -2%, SQ -1.8%, BHP -1.8%, ASML -1.8%, TZOO -1.6%, ING -1.5%, KR -1.5%, I -1.4%, APLE -1.2%, WMT -1.1%, JPM -1.1%, HPP -1%, RDS.A -1%, C -0.9%, RIO -0.9%

Читайте на SMART-LAB:

📢 Открыта книга заявок на два новых выпуска облигаций от ГК «А101»

На этой неделе ГК «А101» разместит два выпуска облигаций на сумму не менее 3 млрд рублей. Прием заявок уже открыт и продлится до 24 декабря, 15:00 по московскому времени. Организаторами...

A101

10:59

Alexeevlive: зарабатываем в прямом эфире

Авторский стрим Сергея Алексеева – трейдера, который 14 лет живёт рынком. Он не рассказывает теорию. Он не рисует сделки на истории. Он торгует вживую, показывает свои реальные входы,...

LiveInvestingGroup

10:03

🎄 Ресейл — символ разумного потребления в новом году

🎁 В конце года многие подводят итоги и пересматривают отношение к деньгам, вещам и собственным решениям. И всё чаще возникает вопрос не только о том, как тратить, но и как выбирать —...

МГКЛ

10:08

Ваш любимый еженедельный мозговой штурм W#113

Доброго вечера! В этом году без новогоднего подарка от ЦБ: Неделю назад писали , что ЦБ обычно разочаровывает своими решениями. В этот раз вышло также. Общий рынок радикально сильно зависит от...